A study looking at automated insulin delivery technology from Sequel Med Tech highlighted the ability to address delayed occlusion detection. According to Sequel, an insulin pump’s failure to deliver insulin in the right amount at the right time is a preventable cause of hospitalization. The company says advances in insulin delivery technology so far fail […]
Clinical Trials
Glucotrack has more data backing implantable glucose monitor, plans for human trials this year
Glucotrack announced the completion of a second long-term preclinical study for its implantable continuous blood glucose monitor (CBGM). The study further validates the CBGM’s sustained accuracy, the company says. It demonstrated a mean absolute relative difference (MARD) — a measurement of CGM accuracy — of 4.7% at day 90. MARD measures the average difference between […]
Study highlights benefits of automated insulin delivery for children in UK
A study in the UK demonstrated significant improvements in HbA1c for users of automated insulin delivery technologies. This comes on the heels of a UK NHS initiative to provide tens of thousands of children and adults with type 1 diabetes in the country with an artificial pancreas. The study aimed to assess the efficacy of […]
Concept Medical enrolls first patient in drug-coated balloon study
Concept Medical announced today that it commenced the FDA investigational device exemption (IDE) study of its MagicTouch system. MagicTouch, a sirolimus drug-coated balloon (DCB), treats in-stent restenosis (ISR) in coronary artery disease (CAD). Dr. Said Ashraf enrolled the first patient in the MAGICAL-ISR study at the AtlantiCare Institute in Atlantic City, New Jersey. The balloon […]
Glucotrack expands CGM tech to spinal epidural space
Glucotrack (Nasdaq:GCTK) announced today that it plans to expand its glucose monitoring technology to measure glucose in the epidural space. Rutherford, New Jersey-based Glucotrack said CGM taking readings in the spinal epidural space could integrate with existing treatments for painful diabetic neuropathy (PDN). Specifically, Glucotrack sees spinal cord stimulation (SCS) technology as a potential integration […]
OM1, Medtronic partner on drug-eluting implant study
OM1 today announced positive results from its partnership with Medtronic (NYSE:MDT) evaluating the Propel corticosteroid-eluting implants. The Propel bioabsorbable implant family came to Medtronic through its acquisition of IntersectENT in 2022. OM1 and Medtronic partnered on their study to focus on healthcare resource use and long-term outcomes in patients with chronic rhinosinusitis (CRS) who underwent […]
The biggest diabetes tech news out of ATTD 2024
Catch up on the latest in diabetes tech from Dexcom, Abbott, Roche Diabetes Care, Insulet, Medtronic and Know Labs. Every year, the diabetes community comes together for the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). In this year’s 17th installment, some of the biggest names shared new studies and technologies set to […]
Medtronic highlights global performance of MiniMed 780G automated insulin delivery system
Medtronic (NYSE:MDT) shared new clinical and real-world evidence backing the use of its MiniMed 780G system around the world. Data shared at ATTD 2024 in Florence, Italy, included the largest set of data from early users in the U.S. Results built upon three-year data from more than 100,000 real-world users who outperformed international time in […]
Know Labs has positive accuracy data for non-invasive glucose monitor
Know Labs (NYSE:KNW) announced interim results highlighting the accuracy of its non-invasive glucose monitoring sensor. Seattle-based Know Labs conducted a study evaluating its proprietary radiofrequency (RF) dielectric sensor. The sensor non-invasively measured blood glucose in participants with prediabetes and type 2 diabetes. It used venous blood as a comparative reference. Know Labs reported a mean […]
Insulet shares data demonstrating Omnipod 5’s superiority to pump therapy
Insulet (Nasdaq:PODD) today announced positive results from a clinical trial pitting its Omnipod 5 against non-automated insulin therapy. Acton, Massachusetts-based Insulet conducted its first randomized controlled trial showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 automated insulin delivery (AID) system. The company presented results at the Advanced Technologies […]
